000 | 01767 a2200481 4500 | ||
---|---|---|---|
005 | 20250513195735.0 | ||
264 | 0 | _c19991214 | |
008 | 199912s 0 0 eng d | ||
022 | _a0008-5472 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aToretsky, J A | |
245 | 0 | 0 |
_aPhosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. _h[electronic resource] |
260 |
_bCancer research _cNov 1999 |
||
300 |
_a5745-50 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 |
_aAndrostadienes _xpharmacology |
650 | 0 | 4 |
_aAntineoplastic Agents _xantagonists & inhibitors |
650 | 0 | 4 |
_aApoptosis _xgenetics |
650 | 0 | 4 | _aCaspase 3 |
650 | 0 | 4 |
_aCaspases _xmetabolism |
650 | 0 | 4 |
_aCell Transformation, Neoplastic _xchemically induced |
650 | 0 | 4 | _aDNA Fragmentation |
650 | 0 | 4 |
_aDoxorubicin _xantagonists & inhibitors |
650 | 0 | 4 |
_aEnzyme Activation _xdrug effects |
650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aIn Situ Nick-End Labeling |
650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xpharmacology |
650 | 0 | 4 |
_aNeoplasm Proteins _xantagonists & inhibitors |
650 | 0 | 4 |
_aPhosphatidylinositol 3-Kinases _xmetabolism |
650 | 0 | 4 | _aPhosphoinositide-3 Kinase Inhibitors |
650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xphysiology |
650 | 0 | 4 | _aProto-Oncogene Proteins |
650 | 0 | 4 | _aProto-Oncogene Proteins c-akt |
650 | 0 | 4 | _aReceptor, IGF Type 1 |
650 | 0 | 4 |
_aSarcoma, Ewing _xenzymology |
650 | 0 | 4 |
_aTumor Cells, Cultured _xdrug effects |
650 | 0 | 4 | _aWortmannin |
700 | 1 | _aThakar, M | |
700 | 1 | _aEskenazi, A E | |
700 | 1 | _aFrantz, C N | |
773 | 0 |
_tCancer research _gvol. 59 _gno. 22 _gp. 5745-50 |
|
999 |
_c10538888 _d10538888 |